Skip to main content
Erschienen in: Rheumatology International 3/2008

01.01.2008 | Case Report

Clinical characteristics of lupus myocarditis in Korea

verfasst von: Jae-Wook Chung, Dai-Yeol Joe, Han-Jung Park, Hyoun-Ah Kim, Hae-Sim Park, Chang-Hee Suh

Erschienen in: Rheumatology International | Ausgabe 3/2008

Einloggen, um Zugang zu erhalten

Abstract

Clinically important myocarditis is an unusual feature in systemic lupus erythematosus (SLE). We describe the clinical characteristics, management and outcomes of five SLE patients who developed severe left ventricular dysfunction. Four patients were female with mean age of 36.4 years. Three patients had both lupus myocarditis and lupus nephritis. Four patients had raised anti-dsDNA antibody titer and low complement level and two patients had positive IgG anticardiolipin antibody. Three patients were treated by high-dose corticosteroids, one patient by intravenous pulse methylprednisolone, and one patient by intravenous immunoglobulin and pulse cyclophosphamide with high dose corticosteroids. Left ventricular function improved markedly in four patients and all of them had no recurrence of lupus myocarditis up to follow-up of 33 months. However, one patient, who showed no improvement of left ventricular function, was expired due to sudden cardiac arrest. Lupus myocarditis should be treated by immunosuppressive therapy with high-dose corticosteroids and mostly the prognosis might be good with early treatment.
Literatur
1.
Zurück zum Zitat D’Cruz D, Khamashta M, Huges GRV (2001) Cardiovascular manifestation of systemic lupus erythematosus. In: Wallace DJ, Hahn BH (eds) Dubois’ lupus erythematous. Lippincott Williams and Wilkins, Philadelphia pp 645 D’Cruz D, Khamashta M, Huges GRV (2001) Cardiovascular manifestation of systemic lupus erythematosus. In: Wallace DJ, Hahn BH (eds) Dubois’ lupus erythematous. Lippincott Williams and Wilkins, Philadelphia pp 645
2.
Zurück zum Zitat Kao AH, Manzi S (2002) How to manage patients with cardiopulmonary disease? Best Pract Res Clin Rheumatol 16:211–227PubMedCrossRef Kao AH, Manzi S (2002) How to manage patients with cardiopulmonary disease? Best Pract Res Clin Rheumatol 16:211–227PubMedCrossRef
3.
Zurück zum Zitat Wijetunga M, Rockson S (2002) Myocarditis in systemic lupus erythematosus. Am J Med 113:419–423PubMedCrossRef Wijetunga M, Rockson S (2002) Myocarditis in systemic lupus erythematosus. Am J Med 113:419–423PubMedCrossRef
4.
Zurück zum Zitat Moder KG, Miller TD, Tazelaar HD (1999) Cardiac involvement in systemic lupus erythematosus. Mayo Clin Proc 74:275–284PubMedCrossRef Moder KG, Miller TD, Tazelaar HD (1999) Cardiac involvement in systemic lupus erythematosus. Mayo Clin Proc 74:275–284PubMedCrossRef
5.
Zurück zum Zitat Sasson Z, Rasooly Y, Chow CW, Marshall S, Urowitz MB (1992) Impairment of left ventricular diastolic function in systemic lupus erythematosus. Am J Cardiol 69:1629–1634PubMedCrossRef Sasson Z, Rasooly Y, Chow CW, Marshall S, Urowitz MB (1992) Impairment of left ventricular diastolic function in systemic lupus erythematosus. Am J Cardiol 69:1629–1634PubMedCrossRef
6.
Zurück zum Zitat Cervera R, Font J, Pare C et al (1992) Cardiac disease in systemic lupus erythematosus: prospective study of 70 patients. Ann Rheum Dis 51:156–159PubMed Cervera R, Font J, Pare C et al (1992) Cardiac disease in systemic lupus erythematosus: prospective study of 70 patients. Ann Rheum Dis 51:156–159PubMed
7.
Zurück zum Zitat Doherty NE, Siegel RJ (1985) Cardiovascular manifestations of systemic lupus erythematosus. Am Heart J 110:1257–1265PubMedCrossRef Doherty NE, Siegel RJ (1985) Cardiovascular manifestations of systemic lupus erythematosus. Am Heart J 110:1257–1265PubMedCrossRef
8.
Zurück zum Zitat Feldman AM, McNamara D (2000) Myocarditis. N Eng J Med 343:1388–1398CrossRef Feldman AM, McNamara D (2000) Myocarditis. N Eng J Med 343:1388–1398CrossRef
9.
Zurück zum Zitat Murphy JG, Franz RP (2003) Endomyocardial biopsy in myocarditis. In: Cooper LT (Ed) Myocarditis: from bench to bedside. Humana, Totowa Murphy JG, Franz RP (2003) Endomyocardial biopsy in myocarditis. In: Cooper LT (Ed) Myocarditis: from bench to bedside. Humana, Totowa
10.
Zurück zum Zitat Noutsias M, Pauschinger M, Poller WC, Schultheiss HP, Kuhl U (2003) Current insights into the pathogenesis, diagnosis and therapy of inflammatory cardiomyopathy. Heart Fail Monit 3:127–135PubMed Noutsias M, Pauschinger M, Poller WC, Schultheiss HP, Kuhl U (2003) Current insights into the pathogenesis, diagnosis and therapy of inflammatory cardiomyopathy. Heart Fail Monit 3:127–135PubMed
11.
Zurück zum Zitat Biadani AK, Roberts JL, Schwartz MM, Lewis EJ (1980) Immunopathology of cardiac lesions in fatal systemic lupus erythematosus. Am J Med 69:849–858CrossRef Biadani AK, Roberts JL, Schwartz MM, Lewis EJ (1980) Immunopathology of cardiac lesions in fatal systemic lupus erythematosus. Am J Med 69:849–858CrossRef
12.
Zurück zum Zitat Logar D, Kveder T, Rozman B, Dovovisek J (1990) Possible association between anti-Ro antibodies and myocarditis or cardiac conduction defects in adults with systemic lupus erythematosus. Ann Rheum Dis 49:627–629PubMedCrossRef Logar D, Kveder T, Rozman B, Dovovisek J (1990) Possible association between anti-Ro antibodies and myocarditis or cardiac conduction defects in adults with systemic lupus erythematosus. Ann Rheum Dis 49:627–629PubMedCrossRef
13.
Zurück zum Zitat Leung WH, Wong KL, Lau CP, Wong CK, Liu HW (1990) Association between antiphospholipid antibodies and cardiac abnormalities in patients with systemic lupus erythematosus. Am J Med 89:411–419PubMedCrossRef Leung WH, Wong KL, Lau CP, Wong CK, Liu HW (1990) Association between antiphospholipid antibodies and cardiac abnormalities in patients with systemic lupus erythematosus. Am J Med 89:411–419PubMedCrossRef
14.
Zurück zum Zitat Comin-Colet J, Saches-Corral MA, Alegre-Sancho JJ, Valverde J, Lopez-Gomez D, Sabate X et al (2001) Complete heart block in an adult with systemic lupus erythematosus and recent onset of hydroxychloroquine therapy. Lupus 10:59–62PubMedCrossRef Comin-Colet J, Saches-Corral MA, Alegre-Sancho JJ, Valverde J, Lopez-Gomez D, Sabate X et al (2001) Complete heart block in an adult with systemic lupus erythematosus and recent onset of hydroxychloroquine therapy. Lupus 10:59–62PubMedCrossRef
15.
Zurück zum Zitat Law WG, Thong BY, Lian TY, Kong KO, Chng HH (2005) Acute lupus myocarditis: clinical features and outcome of an oriental series. Lupus 14:827–831PubMedCrossRef Law WG, Thong BY, Lian TY, Kong KO, Chng HH (2005) Acute lupus myocarditis: clinical features and outcome of an oriental series. Lupus 14:827–831PubMedCrossRef
16.
Zurück zum Zitat Mason JW, O’Connel JB, Herskowitz A, Rose NR, McManus BM, Billingham ME, Moon TE (1995) For the myocarditis treatment trial investigators. A clinical trial of immunosuppressive therapy for myocarditis. N Eng J Med 333:269–275CrossRef Mason JW, O’Connel JB, Herskowitz A, Rose NR, McManus BM, Billingham ME, Moon TE (1995) For the myocarditis treatment trial investigators. A clinical trial of immunosuppressive therapy for myocarditis. N Eng J Med 333:269–275CrossRef
17.
Zurück zum Zitat McNamara DM, Holubkov R, Starling RC, Dec GW, Loh E, Torre-Amione G, Gass A, Janosko K, Tokarcznk T, Kessler P, Mann DL, Feldman AM (2001) Controlled trial of intravenous immunoglobulin in recent-onset dialted cardiomyopathy. Circulation 103:2254–2259PubMed McNamara DM, Holubkov R, Starling RC, Dec GW, Loh E, Torre-Amione G, Gass A, Janosko K, Tokarcznk T, Kessler P, Mann DL, Feldman AM (2001) Controlled trial of intravenous immunoglobulin in recent-onset dialted cardiomyopathy. Circulation 103:2254–2259PubMed
18.
Zurück zum Zitat Frustaci A, Gentiloni N, Caldarulo M (1996) Acute myocarditis and left ventricular aneurysm as presentations of systemic lupus erythematosus. Chest 109:282–284PubMed Frustaci A, Gentiloni N, Caldarulo M (1996) Acute myocarditis and left ventricular aneurysm as presentations of systemic lupus erythematosus. Chest 109:282–284PubMed
19.
Zurück zum Zitat Chan YK, Li EK, Tam LS, Chow LT, Ng HK (2003) Intravenous cyclophosphamide improves cardiac dysfunction in lupus myocarditis. Scand J Rheumatol 32:306–308PubMedCrossRef Chan YK, Li EK, Tam LS, Chow LT, Ng HK (2003) Intravenous cyclophosphamide improves cardiac dysfunction in lupus myocarditis. Scand J Rheumatol 32:306–308PubMedCrossRef
20.
Zurück zum Zitat Naarendorp M, Kerr LD, Khan AS, Ornstein MH (1999) Dramatic improvement of left ventricular function after cytotoxic therapy in lupus patients with acute cardiomyopathy: report of six cases. J Rheumatol 26:2257–2260PubMed Naarendorp M, Kerr LD, Khan AS, Ornstein MH (1999) Dramatic improvement of left ventricular function after cytotoxic therapy in lupus patients with acute cardiomyopathy: report of six cases. J Rheumatol 26:2257–2260PubMed
21.
Zurück zum Zitat Sherer Y, Levy Y, Shoenfeld Y (1999) Marked improvement of severe cardiac dysfunction after one course of intravenous immunoglobulin in a patient with systemic lupus erythematosus. Clin Rheumatol 18:238–240PubMedCrossRef Sherer Y, Levy Y, Shoenfeld Y (1999) Marked improvement of severe cardiac dysfunction after one course of intravenous immunoglobulin in a patient with systemic lupus erythematosus. Clin Rheumatol 18:238–240PubMedCrossRef
22.
Zurück zum Zitat Jacques E, Sophie R, Patrick A, Didier C, Xavier M (2004) Specific cardiomyopathy in lupus patients: report of three cases. Joint Bone Spine 71:66–69CrossRef Jacques E, Sophie R, Patrick A, Didier C, Xavier M (2004) Specific cardiomyopathy in lupus patients: report of three cases. Joint Bone Spine 71:66–69CrossRef
23.
Zurück zum Zitat Doria A, Iaccarino L, Sarzi-Puttini P, Atzeni F, Turriel M, Petri MA (2005) Cardiac involvement in systemic lupus erythematosus. Lupus 14:683–686PubMedCrossRef Doria A, Iaccarino L, Sarzi-Puttini P, Atzeni F, Turriel M, Petri MA (2005) Cardiac involvement in systemic lupus erythematosus. Lupus 14:683–686PubMedCrossRef
24.
Zurück zum Zitat Lazzerini PE, Acampa M, Guideri F, Capecchi PL, Campanella V, Morozzi G et al (2004) Prolongation of the corrected QT intervals in adult patients with anti-Ro/SSA positive connective tissue diseases. Arthritis Rheum 50:1248–1252PubMedCrossRef Lazzerini PE, Acampa M, Guideri F, Capecchi PL, Campanella V, Morozzi G et al (2004) Prolongation of the corrected QT intervals in adult patients with anti-Ro/SSA positive connective tissue diseases. Arthritis Rheum 50:1248–1252PubMedCrossRef
Metadaten
Titel
Clinical characteristics of lupus myocarditis in Korea
verfasst von
Jae-Wook Chung
Dai-Yeol Joe
Han-Jung Park
Hyoun-Ah Kim
Hae-Sim Park
Chang-Hee Suh
Publikationsdatum
01.01.2008
Verlag
Springer-Verlag
Erschienen in
Rheumatology International / Ausgabe 3/2008
Print ISSN: 0172-8172
Elektronische ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-007-0414-6

Weitere Artikel der Ausgabe 3/2008

Rheumatology International 3/2008 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.